

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	8	2.4	327.1	(140.8-644.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	3.3	150.1	(48.4-350.2)
Female	25	19.3	129.3	(83.7-190.9)	Female	4	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	9	7.1	127.6	(58.2-242.3)	<u>Ovary</u>				
Female	5	4.4	114.6	(36.9-267.4)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	33	25.4	129.9	(89.4-182.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.4	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	3.5	169.3	(61.8-368.6)
Male	3	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	82	82.7	99.1	(78.8-123.0)
Female	0	0.4	nc	(nc-nc)	Female	72	59.2	121.7	(95.2-153.2)
<u>Lung and Bronchus</u>									
Male	3	11.2	nc	(nc-nc)					
Female	4	7.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.1	153.1	(93.5-236.5)	Male	10	8.5	117.0	(56.0-215.1)
Female	5	5.1	97.8	(31.5-228.2)	Female	11	7.1	154.0	(76.8-275.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	5	2.2	224.9	(72.5-524.8)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.4	94.1	(37.7-193.9)
Female	54	53.1	101.7	(76.4-132.7)	Female	6	6.6	90.7	(33.1-197.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	5.1	97.3	(31.4-227.1)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	13	15.6	83.3	(44.3-142.5)	<u>Ovary</u>				
Female	12	16.7	71.9	(37.1-125.6)	Female	5	5.0	99.5	(32.1-232.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.4	208.0	(83.3-428.6)	Male	7	4.2	165.2	(66.2-340.5)
Female	0	1.1	nc	(nc-nc)	Female	7	4.8	145.0	(58.1-298.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	59	47.6	123.9	(94.3-159.8)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.0	nc	(nc-nc)
Male	9	7.0	128.8	(58.8-244.4)	Female	0	1.9	nc	(nc-nc)
Female	5	4.4	113.3	(36.5-264.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.0	100.3	(45.8-190.5)
Male	7	4.7	148.5	(59.5-305.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.7	134.7	(43.4-314.4)	Female	13	12.2	106.3	(56.6-181.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.7	nc	(nc-nc)	Male	213	173.2	123.0	(107.0-140.7)
Female	0	1.4	nc	(nc-nc)	Female	190	183.2	103.7	(89.5-119.5)
<u>Lung and Bronchus</u>									
Male	28	24.0	116.8	(77.6-168.8)					
Female	31	26.5	116.9	(79.4-166.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	1.4	349.6	(112.7-815.8)	Male	2	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	8	5.3	150.7	(64.9-297.0)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	5	1.8	284.1	(91.6-663.0)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	20.5	92.5	(55.7-144.4)
Female	0	0.1	nc	(nc-nc)	Female	19	18.5	102.6	(61.7-160.2)
<u>Lung and Bronchus</u>									
Male	1	2.8	nc	(nc-nc)					
Female	3	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.7	93.7	(46.7-167.6)	Male	6	8.3	72.0	(26.3-156.8)
Female	2	4.0	nc	(nc-nc)	Female	1	6.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	5	1.5	338.5	(109.1-790.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
Female	47	46.1	101.9	(74.9-135.6)	Female	4	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	5	5.4	92.3	(29.8-215.5)
<u>Colon / Rectum</u>					Female	5	2.2	227.6	(73.3-531.1)
Male	12	15.0	79.9	(41.2-139.6)	<u>Ovary</u>				
Female	12	13.8	87.2	(45.0-152.3)	Female	6	4.3	139.4	(50.9-303.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	36	48.3	74.5	(52.2-103.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	1	7.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	5	3.6	137.7	(44.4-321.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.9	124.2	(61.9-222.2)
Male	5	4.6	108.3	(34.9-252.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.2	nc	(nc-nc)	Female	11	10.3	107.2	(53.4-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.7	nc	(nc-nc)	Male	136	168.6	80.7	(67.7-95.4)
Female	2	1.1	nc	(nc-nc)	Female	164	154.7	106.0	(90.4-123.6)
<u>Lung and Bronchus</u>									
Male	22	21.8	100.9	(63.2-152.8)					
Female	24	20.3	118.3	(75.7-176.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.1	111.7	(66.1-176.5)	Male	21	9.2	229.2	(141.8-350.4)
Female	9	5.9	153.5	(70.0-291.3)	Female	10	5.9	168.6	(80.7-310.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.8	140.7	(70.2-251.8)
Female	68	47.4	143.3	(111.3-181.7)	Female	5	6.9	72.7	(23.4-169.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.3	nc	(nc-nc)	Male	9	5.2	173.2	(79.0-328.8)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	19	17.9	106.3	(64.0-166.0)	<u>Ovary</u>				
Female	12	18.4	65.2	(33.6-113.8)	Female	6	4.8	123.8	(45.2-269.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.0	124.2	(40.0-289.9)	Male	4	5.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	62	60.7	102.1	(78.3-130.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.6	nc	(nc-nc)
Male	7	7.5	92.8	(37.2-191.1)	Female	2	2.2	nc	(nc-nc)
Female	7	4.4	160.0	(64.1-329.7)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.6	nc	(nc-nc)
Male	6	5.0	119.5	(43.6-260.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	7	11.6	60.5	(24.3-124.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	209	202.3	103.3	(89.8-118.3)
Female	1	1.4	nc	(nc-nc)	Female	182	179.0	101.7	(87.4-117.6)
<u>Lung and Bronchus</u>									
Male	21	30.0	70.0	(43.3-106.9)					
Female	24	29.5	81.4	(52.1-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	37.7	71.6	(47.2-104.2)	Male	32	25.2	127.0	(86.8-179.3)
Female	24	13.7	175.2	(112.2-260.7)	Female	21	19.9	105.3	(65.1-160.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.3	109.5	(47.1-215.7)	Male	9	6.4	141.1	(64.4-267.9)
Female	3	6.2	nc	(nc-nc)	Female	8	5.0	161.0	(69.3-317.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	18	21.8	82.6	(48.9-130.6)
Female	194	147.1	131.9	(114.0-151.8)	Female	20	17.9	112.0	(68.4-172.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.6	89.9	(29.0-209.7)	Male	22	15.5	141.5	(88.7-214.3)
<u>Colon / Rectum</u>					Female	7	7.2	97.8	(39.2-201.5)
Male	49	46.2	106.1	(78.5-140.3)	<u>Ovary</u>				
Female	47	45.0	104.3	(76.7-138.8)	Female	10	13.9	71.8	(34.4-132.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	10.1	98.9	(47.3-181.8)	Male	13	12.3	105.7	(56.2-180.7)
Female	6	2.8	211.7	(77.3-460.8)	Female	14	12.9	108.4	(59.2-181.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.0	nc	(nc-nc)	Male	153	147.7	103.6	(87.8-121.4)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.8	90.4	(38.9-178.2)
Male	20	21.0	95.4	(58.3-147.4)	Female	7	5.1	137.9	(55.2-284.1)
Female	11	12.2	90.5	(45.1-161.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.8	nc	(nc-nc)
Male	3	5.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.7	nc	(nc-nc)	Male	12	8.3	144.6	(74.6-252.7)
<u>Leukemia</u>					Female	32	25.8	124.0	(84.8-175.0)
Male	21	13.8	151.8	(93.9-232.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	10.2	156.1	(89.2-253.6)	Female	38	33.6	113.1	(80.0-155.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	11.2	124.5	(68.0-209.0)	Male	537	517.0	103.9	(95.3-113.0)
Female	4	3.8	nc	(nc-nc)	Female	589	502.9	117.1	(107.8-127.0)
<u>Lung and Bronchus</u>									
Male	64	70.5	90.8	(70.0-116.0)					
Female	66	72.0	91.7	(70.9-116.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	28.4	74.0	(45.8-113.1)	Male	7	19.5	36.0	(14.4-74.1)
Female	11	12.0	91.3	(45.5-163.5)	Female	4	18.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	6.3	174.5	(87.0-312.3)	Male	2	4.7	nc	(nc-nc)
Female	1	5.9	nc	(nc-nc)	Female	7	4.2	165.0	(66.1-340.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	21	17.0	123.3	(76.3-188.4)
Female	81	117.7	68.8	(54.6-85.5)	Female	13	15.6	83.5	(44.4-142.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.2	153.0	(65.9-301.5)	Male	8	11.2	71.1	(30.6-140.2)
<u>Colon / Rectum</u>					Female	8	6.1	131.6	(56.7-259.4)
Male	28	34.5	81.2	(53.9-117.3)	<u>Ovary</u>				
Female	42	40.5	103.7	(74.7-140.2)	Female	6	11.7	51.2	(18.7-111.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.3	68.6	(22.1-160.1)	Male	9	9.1	98.6	(45.0-187.1)
Female	3	2.4	nc	(nc-nc)	Female	12	11.5	104.3	(53.8-182.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.3	nc	(nc-nc)	Male	76	104.0	73.1	(57.6-91.4)
Female	1	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	6.6	182.2	(94.0-318.2)
Male	19	15.4	123.2	(74.1-192.4)	Female	11	4.8	229.5	(114.4-410.7)
Female	10	10.1	99.2	(47.5-182.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.1	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	6	6.9	87.1	(31.8-189.6)
<u>Leukemia</u>					Female	30	24.5	122.4	(82.6-174.8)
Male	14	11.3	123.5	(67.4-207.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	9.8	nc	(nc-nc)	Female	18	26.0	69.2	(41.0-109.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.1	136.2	(67.9-243.7)	Male	359	386.7	92.8	(83.5-103.0)
Female	4	3.2	nc	(nc-nc)	Female	358	428.3	83.6	(75.2-92.7)
<u>Lung and Bronchus</u>									
Male	76	51.6	147.4	(116.1-184.5)					
Female	53	58.9	89.9	(67.3-117.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	4.9	183.4	(83.7-348.2)	Male	9	3.1	291.4	(133.0-553.2)
Female	2	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	15	16.4	91.7	(51.3-151.2)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	4	5.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.7	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	25	17.9	139.5	(90.3-206.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	83	63.5	130.6	(104.0-161.9)
Female	0	0.4	nc	(nc-nc)	Female	40	55.0	72.7	(51.9-99.0)
<u>Lung and Bronchus</u>									
Male	11	8.9	123.4	(61.5-220.8)					
Female	1	8.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	10	5.8	171.4	(82.0-315.1)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.7	77.7	(28.4-169.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	16	24.2	66.0	(37.7-107.3)
Female	0	0.2	nc	(nc-nc)	Female	21	20.3	103.4	(64.0-158.0)
<u>Lung and Bronchus</u>									
Male	2	3.2	nc	(nc-nc)					
Female	5	2.9	172.7	(55.7-403.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.2	116.2	(42.4-252.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	18.5	108.3	(66.1-167.3)
Female	0	0.1	nc	(nc-nc)	Female	13	14.6	88.8	(47.3-151.9)
<u>Lung and Bronchus</u>									
Male	4	2.4	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	63.7	102.1	(78.8-130.1)	Male	26	41.0	63.4	(41.4-92.9)
Female	16	25.8	61.9	(35.4-100.6)	Female	17	34.1	49.8	(29.0-79.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.8	76.6	(34.9-145.3)	Male	13	10.4	125.0	(66.5-213.8)
Female	14	10.7	131.4	(71.8-220.5)	Female	6	9.2	65.2	(23.8-142.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	43	35.9	119.8	(86.7-161.3)
Female	242	242.2	99.9	(87.7-113.3)	Female	32	32.4	98.9	(67.6-139.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.9	101.5	(46.3-192.7)	Male	24	24.9	96.2	(61.6-143.2)
<u>Colon / Rectum</u>					Female	18	12.5	144.3	(85.5-228.1)
Male	57	76.0	75.0	(56.8-97.2)	<u>Ovary</u>				
Female	98	86.4	113.4	(92.1-138.2)	Female	19	24.1	79.0	(47.5-123.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	16.6	108.3	(64.1-171.1)	Male	20	20.4	98.2	(59.9-151.6)
Female	2	5.3	nc	(nc-nc)	Female	24	24.8	97.0	(62.1-144.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	5.3	nc	(nc-nc)	Male	216	241.3	89.5	(78.0-102.3)
Female	3	4.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	27	14.7	184.0	(121.2-267.8)
Male	24	33.7	71.1	(45.6-105.9)	Female	14	10.1	138.7	(75.7-232.7)
Female	21	20.7	101.5	(62.8-155.2)	<u>Testis</u>				
<u>Larynx</u>					Male	10	8.3	120.0	(57.4-220.6)
Male	6	9.7	61.7	(22.5-134.4)	<u>Thyroid</u>				
Female	5	2.9	172.7	(55.6-402.9)	Male	4	13.0	nc	(nc-nc)
<u>Leukemia</u>					Female	25	40.7	61.4	(39.7-90.6)
Male	20	22.9	87.3	(53.3-134.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	18.8	79.9	(44.7-131.7)	Female	55	55.0	100.1	(75.4-130.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	18.2	99.0	(58.7-156.5)	Male	815	850.9	95.8	(89.3-102.6)
Female	8	6.8	117.6	(50.6-231.8)	Female	877	875.8	100.1	(93.6-107.0)
<u>Lung and Bronchus</u>									
Male	150	116.9	128.4	(108.6-150.6)					
Female	167	126.9	131.6	(112.4-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	7	5.0	138.7	(55.5-285.7)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	13	7.2	179.8	(95.6-307.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	24.5	93.8	(59.5-140.8)
Female	0	0.1	nc	(nc-nc)	Female	20	17.6	113.4	(69.2-175.1)
<u>Lung and Bronchus</u>									
Male	1	3.5	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.4	204.7	(66.0-477.7)	Male	0	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	8.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	8	3.0	266.1	(114.6-524.3)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	10.2	68.9	(27.6-141.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	28	34.1	82.2	(54.6-118.8)
Female	0	0.2	nc	(nc-nc)	Female	22	30.8	71.5	(44.8-108.2)
<u>Lung and Bronchus</u>									
Male	5	4.6	108.1	(34.8-252.2)					
Female	5	4.4	112.9	(36.4-263.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	12.6	63.5	(27.3-125.1)	Male	8	8.8	90.9	(39.1-179.0)
Female	8	7.3	109.6	(47.2-216.0)	Female	2	9.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.6	65.4	(21.1-152.7)
Female	56	66.0	84.9	(64.1-110.3)	Female	5	9.0	55.7	(17.9-129.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	6	5.4	110.5	(40.3-240.5)
<u>Colon / Rectum</u>					Female	4	3.4	nc	(nc-nc)
Male	19	15.7	120.8	(72.7-188.7)	<u>Ovary</u>				
Female	23	24.0	95.9	(60.8-143.9)	Female	1	6.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	9	7.0	129.3	(59.0-245.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	38	50.0	76.0	(53.8-104.3)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	3.0	233.2	(93.4-480.5)
Male	9	7.3	123.6	(56.4-234.6)	Female	2	2.8	nc	(nc-nc)
Female	9	5.7	157.5	(71.9-299.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	10	10.7	93.4	(44.7-171.7)
Male	1	4.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.2	95.8	(30.9-223.5)	Female	14	14.8	94.4	(51.5-158.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.9	nc	(nc-nc)	Male	159	177.5	89.6	(76.2-104.6)
Female	3	1.9	nc	(nc-nc)	Female	202	240.8	83.9	(72.7-96.3)
<u>Lung and Bronchus</u>									
Male	27	23.6	114.5	(75.5-166.7)					
Female	32	35.8	89.4	(61.2-126.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	9.2	nc	(nc-nc)	Male	15	5.8	258.5	(144.6-426.4)
Female	3	3.1	nc	(nc-nc)	Female	12	4.1	289.3	(149.3-505.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	1.7	358.7	(131.0-780.7)	Male	2	1.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	28	31.7	88.5	(58.8-127.9)	Female	2	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	17	11.1	153.6	(89.4-246.0)	<u>Ovary</u>				
Female	10	10.6	94.8	(45.4-174.3)	Female	4	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	0.6	nc	(nc-nc)	Male	42	32.8	128.2	(92.4-173.3)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	4.8	103.3	(33.3-241.2)	Female	0	1.2	nc	(nc-nc)
Female	7	2.6	268.3	(107.5-552.8)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.1	156.9	(67.6-309.2)
Male	4	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	10	7.0	142.7	(68.3-262.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.6	nc	(nc-nc)	Male	141	119.7	117.8	(99.1-138.9)
Female	0	0.8	nc	(nc-nc)	Female	121	109.9	110.1	(91.4-131.6)
<u>Lung and Bronchus</u>									
Male	15	16.6	90.2	(50.5-148.8)					
Female	14	15.5	90.3	(49.3-151.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	8	6.5	123.5	(53.2-243.4)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	6	9.4	63.9	(23.3-139.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	20	32.3	61.8	(37.8-95.5)
Female	0	0.2	nc	(nc-nc)	Female	24	21.1	113.8	(72.9-169.4)
<u>Lung and Bronchus</u>									
Male	3	4.4	nc	(nc-nc)					
Female	2	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	22.3	85.0	(51.2-132.8)	Male	32	14.9	215.2	(147.2-303.8)
Female	7	8.6	81.6	(32.7-168.1)	Female	11	10.6	103.8	(51.7-185.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	4.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	5	3.4	148.2	(47.8-345.8)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	12.9	69.6	(31.8-132.2)
Female	111	80.9	137.1	(112.8-165.1)	Female	9	10.6	84.8	(38.7-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	9.4	96.1	(43.9-182.5)
<u>Colon / Rectum</u>					Female	3	4.1	nc	(nc-nc)
Male	21	27.4	76.7	(47.5-117.3)	<u>Ovary</u>				
Female	29	29.0	100.0	(67.0-143.6)	Female	11	7.9	139.1	(69.3-248.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.0	nc	(nc-nc)	Male	8	7.3	109.7	(47.2-216.2)
Female	1	1.8	nc	(nc-nc)	Female	5	8.3	60.3	(19.4-140.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	102	86.8	117.5	(95.8-142.7)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	5.2	nc	(nc-nc)
Male	15	12.4	121.2	(67.8-199.9)	Female	0	3.4	nc	(nc-nc)
Female	6	6.8	87.7	(32.0-190.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.8	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	4.9	102.5	(33.0-239.1)
<u>Leukemia</u>					Female	10	12.1	82.7	(39.6-152.1)
Male	14	8.1	173.8	(94.9-291.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.1	nc	(nc-nc)	Female	19	18.3	103.8	(62.5-162.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	6.8	nc	(nc-nc)	Male	279	305.2	91.4	(81.0-102.8)
Female	2	2.3	nc	(nc-nc)	Female	288	288.2	99.9	(88.7-112.2)
<u>Lung and Bronchus</u>									
Male	21	41.5	50.7	(31.3-77.4)					
Female	22	41.8	52.6	(32.9-79.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	9	7.6	117.7	(53.7-223.4)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	7.8	141.9	(70.7-254.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	28	27.8	100.9	(67.0-145.8)
Female	0	0.2	nc	(nc-nc)	Female	20	24.5	81.6	(49.8-126.0)
<u>Lung and Bronchus</u>									
Male	2	3.6	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	5.0	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	5	5.7	88.0	(28.3-205.3)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	20.7	57.9	(29.9-101.1)
Female	0	0.1	nc	(nc-nc)	Female	17	16.7	101.9	(59.3-163.2)
<u>Lung and Bronchus</u>									
Male	1	3.0	nc	(nc-nc)					
Female	2	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.6	150.6	(80.1-257.5)	Male	5	5.4	93.2	(30.0-217.5)
Female	4	3.3	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	24	30.1	79.7	(51.0-118.5)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	15	10.2	146.6	(82.0-241.8)	<u>Ovary</u>				
Female	23	11.0	209.2	(132.6-314.0)	Female	3	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	27	30.0	89.9	(59.2-130.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	4.8	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.3	nc	(nc-nc)	Female	10	6.7	148.5	(71.1-273.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.3	nc	(nc-nc)	Male	104	110.5	94.1	(76.9-114.0)
Female	2	0.9	nc	(nc-nc)	Female	109	108.7	100.2	(82.3-120.9)
<u>Lung and Bronchus</u>									
Male	15	15.4	97.6	(54.6-161.0)					
Female	16	15.8	101.4	(57.9-164.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	36.7	109.1	(78.0-148.6)	Male	28	22.8	122.7	(81.5-177.3)
Female	15	12.8	117.6	(65.8-193.9)	Female	25	17.1	145.9	(94.4-215.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.3	111.8	(44.8-230.3)	Male	4	5.9	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	18	20.0	90.0	(53.3-142.3)
Female	134	125.3	106.9	(89.6-126.7)	Female	25	16.1	155.3	(100.5-229.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.6	nc	(nc-nc)	Male	10	13.7	73.1	(35.0-134.5)
<u>Colon / Rectum</u>					Female	7	6.3	111.1	(44.5-229.0)
Male	40	43.6	91.7	(65.5-124.9)	<u>Ovary</u>				
Female	49	43.2	113.4	(83.9-150.0)	Female	11	12.2	90.4	(45.1-161.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.2	87.3	(37.6-172.1)	Male	16	11.7	137.0	(78.3-222.6)
Female	5	2.6	192.1	(61.9-448.3)	Female	21	12.2	171.6	(106.2-262.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.6	nc	(nc-nc)	Male	151	130.3	115.9	(98.1-135.9)
Female	6	2.1	288.5	(105.4-628.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	8.4	95.0	(40.9-187.2)
Male	22	18.5	118.7	(74.4-179.8)	Female	4	5.0	nc	(nc-nc)
Female	13	10.4	125.1	(66.6-214.0)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.8	234.1	(106.8-444.5)
Male	2	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	8	6.9	116.1	(50.0-228.7)
<u>Leukemia</u>					Female	15	20.8	72.2	(40.4-119.0)
Male	13	13.0	100.4	(53.4-171.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	9.3	129.6	(66.9-226.4)	Female	38	28.0	135.8	(96.1-186.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.0	100.4	(48.0-184.6)	Male	505	472.2	107.0	(97.8-116.7)
Female	6	3.4	176.6	(64.5-384.5)	Female	506	441.6	114.6	(104.8-125.0)
<u>Lung and Bronchus</u>									
Male	70	65.5	106.9	(83.3-135.1)					
Female	67	62.7	106.8	(82.8-135.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	43.1	97.5	(70.3-131.8)	Male	12	27.3	44.0	(22.7-76.9)
Female	22	15.3	144.0	(90.2-218.0)	Female	17	20.1	84.5	(49.2-135.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.5	93.1	(37.3-191.8)	Male	4	7.0	nc	(nc-nc)
Female	5	6.4	78.6	(25.3-183.4)	Female	5	5.5	90.6	(29.2-211.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	20	23.8	84.1	(51.3-129.8)
Female	118	147.4	80.0	(66.2-95.8)	Female	22	19.3	113.9	(71.3-172.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.2	nc	(nc-nc)	Male	14	16.3	85.6	(46.8-143.7)
<u>Colon / Rectum</u>					Female	5	7.5	66.4	(21.4-155.0)
Male	47	51.3	91.6	(67.3-121.8)	<u>Ovary</u>				
Female	44	50.5	87.1	(63.3-117.0)	Female	14	14.5	96.6	(52.8-162.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.9	128.0	(69.9-214.8)	Male	14	13.8	101.2	(55.3-169.8)
Female	2	3.1	nc	(nc-nc)	Female	8	14.6	54.8	(23.6-108.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	193	157.2	122.8	(106.1-141.4)
Female	1	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	9.9	152.1	(85.0-250.8)
Male	29	22.0	131.8	(88.3-189.4)	Female	1	5.8	nc	(nc-nc)
Female	9	12.6	71.5	(32.6-135.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	5.4	nc	(nc-nc)
Male	6	6.3	94.9	(34.7-206.7)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	17	8.5	200.1	(116.5-320.3)
<u>Leukemia</u>					Female	21	24.1	87.3	(54.0-133.4)
Male	19	15.3	124.1	(74.7-193.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.0	81.8	(37.3-155.3)	Female	33	34.2	96.5	(66.4-135.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	11.8	nc	(nc-nc)	Male	586	563.4	104.0	(95.8-112.8)
Female	3	4.1	nc	(nc-nc)	Female	444	525.6	84.5	(76.8-92.7)
<u>Lung and Bronchus</u>									
Male	85	77.7	109.4	(87.4-135.3)					
Female	54	76.9	70.2	(52.7-91.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.8	110.0	(76.6-153.0)	Male	20	19.8	100.9	(61.6-155.9)
Female	13	11.8	110.2	(58.6-188.5)	Female	24	15.1	159.1	(101.9-236.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.6	125.3	(50.2-258.1)	Male	4	5.1	nc	(nc-nc)
Female	5	4.8	105.1	(33.9-245.3)	Female	2	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.9	nc	(nc-nc)	Male	19	17.5	108.6	(65.3-169.6)
Female	110	110.4	99.7	(81.9-120.1)	Female	13	14.7	88.2	(46.9-150.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.9	152.2	(55.6-331.2)	Male	8	11.6	69.0	(29.7-135.9)
<u>Colon / Rectum</u>					Female	2	5.7	nc	(nc-nc)
Male	37	37.4	99.0	(69.7-136.5)	<u>Ovary</u>				
Female	32	39.2	81.7	(55.9-115.3)	Female	8	10.8	73.8	(31.8-145.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	7.9	126.9	(60.8-233.5)	Male	10	10.0	99.8	(47.8-183.6)
Female	3	2.4	nc	(nc-nc)	Female	8	11.3	70.8	(30.5-139.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	95	110.9	85.7	(69.3-104.7)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.2	110.4	(47.5-217.6)
Male	6	16.0	37.5	(13.7-81.6)	Female	6	4.6	131.3	(47.9-285.8)
Female	15	9.4	158.8	(88.8-261.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.7	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	6.0	99.2	(36.2-215.9)
<u>Leukemia</u>					Female	24	17.9	134.4	(86.1-200.0)
Male	11	11.2	98.0	(48.9-175.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.5	106.4	(48.6-202.0)	Female	19	25.1	75.6	(45.5-118.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	8.6	93.3	(40.2-183.8)	Male	363	407.4	89.1	(80.2-98.8)
Female	1	3.1	nc	(nc-nc)	Female	404	397.5	101.6	(92.0-112.0)
<u>Lung and Bronchus</u>									
Male	53	57.0	92.9	(69.6-121.5)					
Female	65	58.3	111.5	(86.1-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.1	138.2	(55.4-284.8)	Male	6	3.6	166.9	(61.0-363.4)
Female	3	2.1	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.1	162.3	(52.3-378.8)
Female	24	21.7	110.6	(70.8-164.6)	Female	4	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	8	6.4	125.3	(54.0-246.9)	<u>Ovary</u>				
Female	1	7.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	31	22.7	136.4	(92.7-193.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.6	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	6	4.9	122.9	(44.9-267.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.7	nc	(nc-nc)	Male	86	74.6	115.2	(92.2-142.3)
Female	0	0.6	nc	(nc-nc)	Female	66	74.4	88.7	(68.6-112.9)
<u>Lung and Bronchus</u>									
Male	6	9.8	61.2	(22.4-133.3)					
Female	4	10.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	33.2	99.4	(68.4-139.6)	Male	42	18.6	226.2	(163.0-305.8)
Female	8	11.3	70.9	(30.5-139.6)	Female	30	12.6	238.9	(161.1-341.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.6	108.3	(34.9-252.8)	Male	4	5.1	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	15	16.2	92.6	(51.8-152.7)
Female	123	98.1	125.4	(104.2-149.6)	Female	13	13.6	95.4	(50.7-163.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.0	nc	(nc-nc)	Male	20	10.4	193.0	(117.8-298.0)
<u>Colon / Rectum</u>					Female	3	5.2	nc	(nc-nc)
Male	41	36.7	111.8	(80.3-151.7)	<u>Ovary</u>				
Female	41	35.5	115.5	(82.9-156.7)	Female	11	9.8	112.7	(56.2-201.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.8	63.8	(20.6-148.8)	Male	9	10.3	87.6	(40.0-166.2)
Female	3	2.4	nc	(nc-nc)	Female	8	10.7	74.9	(32.2-147.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	143	111.7	128.0	(107.9-150.8)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	7.2	nc	(nc-nc)
Male	12	14.9	80.4	(41.5-140.4)	Female	4	4.1	nc	(nc-nc)
Female	14	8.8	158.7	(86.7-266.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	11	13.2	83.6	(41.7-149.6)
Male	11	10.5	104.4	(52.0-186.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	7.4	203.1	(113.6-335.0)	Female	34	23.7	143.7	(99.5-200.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.0	112.5	(51.3-213.6)	Male	450	399.3	112.7	(102.5-123.6)
Female	3	2.9	nc	(nc-nc)	Female	421	360.3	116.9	(106.0-128.6)
<u>Lung and Bronchus</u>									
Male	50	59.3	84.3	(62.5-111.1)					
Female	58	57.8	100.3	(76.2-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.3	123.2	(56.2-234.0)	Male	3	5.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.3	115.5	(37.2-269.6)
Female	24	28.5	84.2	(53.9-125.3)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.1	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.3	nc	(nc-nc)
Male	9	8.9	100.9	(46.0-191.5)	<u>Ovary</u>				
Female	4	7.8	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	2.4	208.8	(67.3-487.2)
Female	1	0.5	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.6	nc	(nc-nc)	Male	27	30.1	89.6	(59.0-130.3)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	11	4.1	266.5	(132.9-476.9)	Female	3	0.9	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	5	1.7	300.7	(96.9-701.7)
<u>Leukemia</u>					Female	5	5.2	95.5	(30.8-222.8)
Male	0	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.8	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	99	102.6	96.5	(78.5-117.5)
Female	1	0.7	nc	(nc-nc)	Female	90	93.2	96.5	(77.6-118.6)
<u>Lung and Bronchus</u>									
Male	9	13.6	66.1	(30.2-125.4)					
Female	13	12.6	102.8	(54.7-175.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	4.5	176.9	(76.2-348.6)	Male	6	3.9	152.3	(55.6-331.6)
Female	1	1.9	nc	(nc-nc)	Female	8	3.9	203.2	(87.5-400.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.4	147.0	(47.4-343.0)
Female	24	27.1	88.7	(56.8-132.0)	Female	2	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.2	nc	(nc-nc)
Male	6	6.6	91.2	(33.3-198.4)	<u>Ovary</u>				
Female	4	7.1	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.5	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	17	21.3	79.7	(46.4-127.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.1	82.3	(26.5-192.1)
Male	0	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	7	5.8	121.4	(48.6-250.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.9	nc	(nc-nc)	Male	76	74.9	101.4	(79.9-127.0)
Female	0	0.6	nc	(nc-nc)	Female	83	85.7	96.8	(77.1-120.0)
<u>Lung and Bronchus</u>									
Male	8	8.8	91.0	(39.2-179.2)					
Female	13	9.8	133.3	(70.9-228.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.2	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	6	3.1	194.0	(70.9-422.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.0	173.8	(69.6-358.1)
Female	26	23.6	110.2	(72.0-161.5)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.1	nc	(nc-nc)
Male	5	8.6	58.2	(18.8-135.9)	<u>Ovary</u>				
Female	4	6.6	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	29	26.7	108.6	(72.7-156.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	11	4.1	268.2	(133.7-480.0)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	7	5.4	129.4	(51.8-266.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	73	94.9	76.9	(60.3-96.8)
Female	1	0.6	nc	(nc-nc)	Female	79	78.5	100.6	(79.7-125.4)
<u>Lung and Bronchus</u>									
Male	6	13.1	45.7	(16.7-99.5)					
Female	6	11.3	52.9	(19.3-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	30.9	129.3	(92.4-176.1)	Male	12	20.9	57.5	(29.7-100.5)
Female	19	10.8	176.7	(106.4-276.0)	Female	13	16.1	80.7	(42.9-137.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.1	147.4	(67.2-279.8)	Male	2	5.2	nc	(nc-nc)
Female	6	5.0	119.4	(43.6-259.8)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	19	18.0	105.4	(63.4-164.5)
Female	121	114.8	105.4	(87.5-125.9)	Female	14	14.2	98.9	(54.0-166.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	16	13.0	123.5	(70.5-200.5)
<u>Colon / Rectum</u>					Female	8	5.7	141.2	(60.8-278.1)
Male	56	37.5	149.4	(112.8-194.0)	<u>Ovary</u>				
Female	33	36.1	91.5	(63.0-128.5)	Female	12	11.0	108.8	(56.2-190.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	8.4	95.4	(41.1-188.0)	Male	11	10.1	108.5	(54.1-194.2)
Female	2	2.2	nc	(nc-nc)	Female	9	10.2	88.0	(40.2-167.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	97	122.8	79.0	(64.1-96.4)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.2	83.2	(30.4-181.0)
Male	17	17.3	98.4	(57.3-157.6)	Female	9	4.1	220.6	(100.7-418.8)
Female	13	9.5	137.4	(73.1-235.1)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.6	nc	(nc-nc)
Male	5	4.9	102.6	(33.1-239.5)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	7	7.0	99.7	(40.0-205.5)
<u>Leukemia</u>					Female	31	21.0	147.6	(100.3-209.5)
Male	17	11.4	149.2	(86.9-239.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	8.3	145.3	(75.0-253.8)	Female	19	26.5	71.7	(43.2-112.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.3	97.0	(44.3-184.2)	Male	426	427.2	99.7	(90.5-109.7)
Female	3	3.0	nc	(nc-nc)	Female	442	396.5	111.5	(101.3-122.4)
<u>Lung and Bronchus</u>									
Male	62	57.6	107.6	(82.5-138.0)					
Female	77	55.1	139.8	(110.3-174.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.1	81.4	(37.1-154.5)	Male	2	7.6	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	36	40.7	88.4	(61.9-122.4)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	18	13.6	132.1	(78.2-208.7)	<u>Ovary</u>				
Female	13	12.4	105.0	(55.9-179.6)	Female	8	3.9	205.2	(88.4-404.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	34	43.7	77.8	(53.9-108.7)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	3	6.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	11	7.5	146.3	(72.9-261.7)
Male	4	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	9	9.4	95.8	(43.7-181.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	133	154.5	86.1	(72.1-102.0)
Female	1	1.0	nc	(nc-nc)	Female	138	139.5	98.9	(83.1-116.8)
<u>Lung and Bronchus</u>									
Male	26	20.5	126.7	(82.7-185.7)					
Female	23	19.6	117.6	(74.5-176.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	4	1.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	15	12.8	116.8	(65.3-192.7)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	6	3.1	191.0	(69.7-415.7)	<u>Ovary</u>				
Female	2	3.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	10.6	66.1	(26.5-136.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	4	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	5	2.8	177.8	(57.3-415.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	31	35.9	86.4	(58.7-122.7)
Female	0	0.3	nc	(nc-nc)	Female	36	42.0	85.8	(60.1-118.8)
<u>Lung and Bronchus</u>									
Male	2	4.4	nc	(nc-nc)					
Female	2	5.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	17.1	70.3	(36.3-122.9)	Male	33	11.1	297.7	(204.9-418.1)
Female	3	5.9	nc	(nc-nc)	Female	15	8.3	179.7	(100.5-296.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	9.7	103.5	(49.6-190.4)
Female	72	63.6	113.2	(88.5-142.5)	Female	9	7.7	117.0	(53.4-222.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	3.1	nc	(nc-nc)
Male	14	20.8	67.4	(36.8-113.1)	<u>Ovary</u>				
Female	17	19.8	86.1	(50.1-137.8)	Female	9	6.1	148.6	(67.8-282.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	4.6	194.8	(88.9-369.8)	Male	3	5.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.1	nc	(nc-nc)	Male	91	68.6	132.6	(106.8-162.9)
Female	5	1.0	490.0	(157.9-1143.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	13	9.3	140.3	(74.7-240.0)	Female	3	2.3	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	14	10.7	130.5	(71.3-219.0)
Male	5	6.2	80.3	(25.9-187.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.5	157.2	(63.0-323.9)	Female	11	14.6	75.3	(37.6-134.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.0	nc	(nc-nc)	Male	251	233.1	107.7	(94.8-121.9)
Female	3	1.6	nc	(nc-nc)	Female	232	216.1	107.4	(94.0-122.1)
<u>Lung and Bronchus</u>									
Male	18	31.5	57.1	(33.8-90.2)					
Female	27	30.0	90.1	(59.4-131.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	14.5	75.8	(37.8-135.7)	Male	10	9.7	103.3	(49.5-190.0)
Female	5	5.3	94.8	(30.6-221.3)	Female	14	7.9	176.2	(96.2-295.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	8.5	82.5	(33.1-170.0)
Female	57	57.0	100.1	(75.8-129.7)	Female	14	6.9	201.5	(110.1-338.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	6	6.0	100.6	(36.7-219.0)
<u>Colon / Rectum</u>					Female	3	2.8	nc	(nc-nc)
Male	15	18.3	81.8	(45.7-134.9)	<u>Ovary</u>				
Female	20	17.9	111.6	(68.1-172.4)	Female	5	5.5	90.6	(29.2-211.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	4.7	127.3	(46.5-277.1)
Female	2	1.1	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.2	nc	(nc-nc)	Male	50	53.7	93.1	(69.1-122.7)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.5	nc	(nc-nc)
Male	12	7.9	152.5	(78.7-266.4)	Female	0	2.0	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.0	244.4	(78.8-570.4)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	5	3.2	155.3	(50.0-362.4)
<u>Leukemia</u>					Female	14	10.3	135.3	(73.9-227.0)
Male	3	5.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.0	nc	(nc-nc)	Female	19	13.0	145.6	(87.6-227.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.2	118.8	(38.3-277.3)	Male	192	195.9	98.0	(84.6-112.9)
Female	1	1.5	nc	(nc-nc)	Female	217	195.6	110.9	(96.7-126.7)
<u>Lung and Bronchus</u>									
Male	33	26.0	127.0	(87.4-178.4)					
Female	29	26.8	108.1	(72.4-155.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	2.4	247.7	(90.5-539.2)	Male	4	1.6	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	6	9.1	65.9	(24.1-143.5)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.7	61.7	(22.5-134.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	32	33.5	95.6	(65.3-134.9)
Female	0	0.2	nc	(nc-nc)	Female	33	30.6	107.8	(74.2-151.4)
<u>Lung and Bronchus</u>									
Male	2	4.6	nc	(nc-nc)					
Female	3	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.0	110.1	(69.0-166.7)	Male	14	12.6	110.9	(60.6-186.1)
Female	6	8.7	69.2	(25.3-150.6)	Female	9	10.4	86.9	(39.7-165.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	11.0	136.9	(76.6-225.9)
Female	74	76.6	96.7	(75.9-121.3)	Female	11	10.5	104.8	(52.3-187.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	8	7.7	104.4	(45.0-205.7)
<u>Colon / Rectum</u>					Female	4	4.0	nc	(nc-nc)
Male	18	23.6	76.2	(45.2-120.5)	<u>Ovary</u>				
Female	15	29.2	51.3	(28.7-84.6)	Female	3	7.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.2	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	11	8.4	131.1	(65.4-234.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	95	74.5	127.6	(103.2-156.0)
Female	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.6	nc	(nc-nc)
Male	11	10.4	105.9	(52.8-189.5)	Female	3	3.5	nc	(nc-nc)
Female	9	6.6	137.2	(62.6-260.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.1	nc	(nc-nc)
Male	5	3.0	167.0	(53.8-389.7)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	7	11.6	60.2	(24.1-124.0)
Male	9	7.0	128.6	(58.7-244.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	6.2	nc	(nc-nc)	Female	17	17.3	98.4	(57.3-157.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.6	nc	(nc-nc)	Male	266	262.3	101.4	(89.6-114.3)
Female	0	2.2	nc	(nc-nc)	Female	228	280.8	81.2	(71.0-92.5)
<u>Lung and Bronchus</u>									
Male	28	36.5	76.8	(51.0-111.0)					
Female	25	40.6	61.6	(39.9-90.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	11.9	134.4	(76.8-218.3)	Male	12	6.8	176.9	(91.3-309.1)
Female	5	4.7	106.0	(34.2-247.4)	Female	9	5.0	180.6	(82.4-342.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	34	39.4	86.2	(59.7-120.5)	Female	4	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	2.1	nc	(nc-nc)
Male	9	13.1	68.4	(31.2-129.9)	<u>Ovary</u>				
Female	7	14.7	47.6	(19.1-98.0)	Female	9	4.0	227.3	(103.7-431.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	3.0	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	5	4.5	111.5	(35.9-260.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	43	43.8	98.3	(71.1-132.4)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.6	nc	(nc-nc)
Male	6	5.6	108.0	(39.4-235.0)	Female	0	1.7	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	8	3.8	213.3	(91.8-420.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	Female	10	9.6	104.7	(50.1-192.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.1	nc	(nc-nc)	Male	139	148.4	93.6	(78.7-110.6)
Female	0	1.2	nc	(nc-nc)	Female	122	147.1	83.0	(68.9-99.1)
<u>Lung and Bronchus</u>									
Male	15	21.9	68.4	(38.2-112.8)					
Female	16	24.4	65.6	(37.5-106.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.6	73.8	(39.2-126.2)	Male	9	11.8	76.1	(34.7-144.4)
Female	8	7.8	103.1	(44.4-203.1)	Female	7	10.5	66.7	(26.7-137.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	5	3.2	154.6	(49.8-360.8)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	10.4	48.1	(15.5-112.1)
Female	81	75.6	107.2	(85.1-133.2)	Female	8	9.8	81.2	(35.0-160.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.7	182.2	(58.7-425.3)	Male	10	7.5	133.4	(63.9-245.4)
<u>Colon / Rectum</u>					Female	5	3.8	132.3	(42.6-308.8)
Male	25	22.0	113.4	(73.4-167.5)	<u>Ovary</u>				
Female	21	26.6	78.8	(48.8-120.5)	Female	8	7.3	108.9	(46.9-214.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	106.9	(34.5-249.5)	Male	4	5.7	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	9	7.5	120.1	(54.8-228.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	78	66.3	117.6	(93.0-146.8)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.1	nc	(nc-nc)
Male	8	9.7	82.1	(35.4-161.8)	Female	2	3.0	nc	(nc-nc)
Female	7	6.4	110.0	(44.1-226.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	15	12.6	119.3	(66.7-196.8)
Male	6	6.5	92.3	(33.7-201.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	5.7	nc	(nc-nc)	Female	13	16.8	77.5	(41.2-132.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.4	nc	(nc-nc)	Male	238	239.9	99.2	(87.0-112.6)
Female	3	2.1	nc	(nc-nc)	Female	255	268.6	94.9	(83.6-107.3)
<u>Lung and Bronchus</u>									
Male	33	32.0	103.1	(71.0-144.8)					
Female	30	38.2	78.5	(52.9-112.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.2	89.5	(53.9-139.8)	Male	18	14.8	121.7	(72.1-192.4)
Female	4	7.6	nc	(nc-nc)	Female	20	12.1	165.5	(101.1-255.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.4	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	7	3.7	188.5	(75.5-388.3)	Female	4	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	12	12.8	93.4	(48.2-163.2)
Female	111	85.0	130.6	(107.4-157.3)	Female	13	10.3	126.5	(67.3-216.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	5	9.6	52.0	(16.8-121.3)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	26	26.6	97.9	(63.9-143.5)	<u>Ovary</u>				
Female	23	25.5	90.2	(57.2-135.4)	Female	8	8.2	97.9	(42.2-192.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.0	133.2	(57.4-262.5)	Male	5	7.1	70.9	(22.9-165.5)
Female	2	1.6	nc	(nc-nc)	Female	10	7.2	138.6	(66.3-254.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	83	89.2	93.0	(74.1-115.3)
Female	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.1	nc	(nc-nc)
Male	9	12.5	72.1	(32.9-136.9)	Female	0	2.9	nc	(nc-nc)
Female	11	6.8	160.9	(80.2-287.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.3	180.9	(66.0-393.7)
Male	4	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	7	5.2	135.6	(54.3-279.5)
<u>Leukemia</u>					Female	22	16.3	135.2	(84.7-204.7)
Male	7	8.1	86.4	(34.6-178.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.9	135.8	(58.5-267.6)	Female	19	19.7	96.3	(58.0-150.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.8	133.3	(60.8-253.0)	Male	281	304.5	92.3	(81.8-103.7)
Female	1	2.2	nc	(nc-nc)	Female	329	289.6	113.6	(101.6-126.6)
<u>Lung and Bronchus</u>									
Male	26	40.0	65.1	(42.5-95.3)					
Female	33	39.2	84.1	(57.9-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.9	nc	(nc-nc)	Male	5	3.5	141.8	(45.7-331.0)
Female	4	1.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	16	17.2	93.2	(53.2-151.3)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	2	6.4	nc	(nc-nc)	<u>Ovary</u>				
Female	5	4.6	108.6	(35.0-253.4)	Female	1	1.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	1.3	449.7	(164.2-978.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	22	22.4	98.1	(61.5-148.5)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.2	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	7	4.3	163.3	(65.4-336.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	61	73.4	83.2	(63.6-106.8)
Female	0	0.4	nc	(nc-nc)	Female	71	56.8	125.1	(97.7-157.8)
<u>Lung and Bronchus</u>									
Male	7	9.3	75.2	(30.1-154.9)					
Female	11	8.2	134.4	(67.0-240.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.9	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	5	8.1	62.1	(20.0-144.9)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	10.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	21	36.4	57.7	(35.7-88.2)
Female	0	0.2	nc	(nc-nc)	Female	20	28.3	70.7	(43.2-109.3)
<u>Lung and Bronchus</u>									
Male	3	5.3	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	5	7.9	63.4	(20.4-147.9)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	6	2.3	262.8	(96.0-572.0)	<u>Ovary</u>				
Female	1	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.7	103.5	(44.6-204.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	26	26.1	99.8	(65.2-146.2)
Female	0	0.2	nc	(nc-nc)	Female	22	27.0	81.5	(51.1-123.4)
<u>Lung and Bronchus</u>									
Male	5	3.3	150.7	(48.6-351.8)					
Female	2	3.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	10	12.5	79.9	(38.3-147.0)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.6	167.7	(61.2-365.0)	Female	3	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	14.7	115.6	(67.3-185.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.4	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	55	51.2	107.5	(81.0-140.0)
Female	0	0.3	nc	(nc-nc)	Female	49	41.3	118.6	(87.7-156.8)
<u>Lung and Bronchus</u>									
Male	7	6.6	105.8	(42.4-218.1)					
Female	6	5.5	109.5	(40.0-238.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	33.3	114.1	(80.8-156.7)	Male	24	22.7	105.5	(67.6-157.0)
Female	11	13.2	83.1	(41.4-148.7)	Female	10	20.0	50.1	(24.0-92.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.1	112.6	(48.5-221.9)	Male	6	5.5	109.5	(40.0-238.4)
Female	7	6.1	115.5	(46.3-238.1)	Female	3	4.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	24	20.0	119.9	(76.8-178.4)
Female	128	136.3	93.9	(78.4-111.7)	Female	15	17.2	87.2	(48.8-143.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.7	nc	(nc-nc)	Male	17	13.5	126.1	(73.4-201.9)
<u>Colon / Rectum</u>					Female	3	6.8	nc	(nc-nc)
Male	48	41.8	114.8	(84.7-152.3)	<u>Ovary</u>				
Female	53	44.2	119.9	(89.8-156.8)	Female	14	13.1	106.6	(58.3-178.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	8.4	95.2	(41.0-187.6)	Male	13	10.7	121.0	(64.4-206.9)
Female	2	2.7	nc	(nc-nc)	Female	14	12.6	111.2	(60.8-186.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.7	136.1	(43.8-317.5)	Male	95	118.6	80.1	(64.8-98.0)
Female	4	2.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	7.9	177.2	(96.8-297.4)
Male	21	18.1	116.3	(72.0-177.8)	Female	13	5.1	253.3	(134.7-433.1)
Female	10	11.3	88.8	(42.5-163.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.8	nc	(nc-nc)
Male	5	4.9	101.9	(32.8-237.8)	<u>Thyroid</u>				
Female	5	1.6	318.6	(102.7-743.5)	Male	8	8.1	99.3	(42.8-195.7)
<u>Leukemia</u>					Female	25	26.6	93.9	(60.8-138.6)
Male	11	13.2	83.1	(41.4-148.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	10.1	128.8	(68.5-220.3)	Female	30	30.1	99.6	(67.2-142.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	9.4	170.6	(97.4-277.0)	Male	475	449.6	105.6	(96.4-115.6)
Female	8	3.6	224.8	(96.8-442.9)	Female	510	478.6	106.6	(97.5-116.2)
<u>Lung and Bronchus</u>									
Male	76	58.8	129.2	(101.8-161.7)					
Female	103	66.4	155.1	(126.6-188.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	21.7	124.7	(82.2-181.4)	Male	13	13.4	97.1	(51.6-166.0)
Female	12	9.6	124.8	(64.4-218.0)	Female	15	11.6	129.7	(72.5-213.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	8	3.5	230.3	(99.2-453.9)
Female	4	3.6	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	11	11.7	94.1	(46.9-168.4)
Female	80	85.6	93.5	(74.1-116.3)	Female	11	11.7	94.0	(46.9-168.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	10	8.0	125.5	(60.1-230.8)
<u>Colon / Rectum</u>					Female	5	4.5	111.9	(36.1-261.2)
Male	26	25.6	101.6	(66.4-148.9)	<u>Ovary</u>				
Female	32	31.9	100.3	(68.6-141.6)	Female	8	8.5	94.4	(40.6-186.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.4	nc	(nc-nc)	Male	8	6.9	116.2	(50.0-229.0)
Female	0	2.0	nc	(nc-nc)	Female	8	9.3	86.3	(37.2-170.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	109	78.3	139.2	(114.3-168.0)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	4.9	202.3	(96.8-372.0)
Male	8	10.9	73.1	(31.5-144.1)	Female	3	3.8	nc	(nc-nc)
Female	8	7.4	107.4	(46.2-211.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	6	3.2	189.2	(69.1-411.8)	<u>Thyroid</u>				
Female	6	1.0	576.7	(210.6-1255.2)	Male	7	4.0	173.1	(69.3-356.6)
<u>Leukemia</u>					Female	14	13.1	106.5	(58.2-178.6)
Male	11	7.5	146.3	(72.9-261.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.6	75.4	(24.3-176.1)	Female	13	19.2	67.6	(36.0-115.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.9	85.3	(27.5-199.1)	Male	354	279.6	126.6	(113.7-140.5)
Female	3	2.5	nc	(nc-nc)	Female	316	313.2	100.9	(90.1-112.6)
<u>Lung and Bronchus</u>									
Male	56	39.2	142.8	(107.8-185.4)					
Female	61	46.9	130.1	(99.5-167.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	111	95.6	116.1	(95.5-139.8)	Male	43	61.7	69.7	(50.5-93.9)
Female	43	40.4	106.5	(77.1-143.5)	Female	24	54.5	44.0	(28.2-65.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	18.1	93.9	(54.6-150.3)	Male	18	15.6	115.2	(68.3-182.1)
Female	12	17.2	69.8	(36.0-121.9)	Female	12	14.4	83.5	(43.1-145.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.8	nc	(nc-nc)	Male	53	54.1	98.0	(73.4-128.1)
Female	280	378.0	74.1	(65.7-83.3)	Female	51	50.8	100.4	(74.7-132.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	14.6	150.6	(94.3-228.0)	Male	46	36.5	125.9	(92.1-167.9)
<u>Colon / Rectum</u>					Female	10	19.5	51.4	(24.6-94.5)
Male	119	114.0	104.4	(86.5-125.0)	<u>Ovary</u>				
Female	149	135.7	109.8	(92.9-129.0)	Female	40	37.4	106.8	(76.3-145.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	24.3	111.0	(73.1-161.5)	Male	39	30.6	127.4	(90.6-174.1)
Female	4	8.3	nc	(nc-nc)	Female	40	38.7	103.3	(73.8-140.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	8.6	93.4	(40.2-184.0)	Male	284	348.5	81.5	(72.3-91.5)
Female	3	7.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	41	22.0	186.7	(134.0-253.3)
Male	53	49.5	107.0	(80.1-139.9)	Female	30	15.9	189.0	(127.5-269.8)
Female	34	32.4	104.8	(72.6-146.4)	<u>Testis</u>				
<u>Larynx</u>					Male	13	14.2	91.4	(48.6-156.3)
Male	25	14.1	177.7	(115.0-262.4)	<u>Thyroid</u>				
Female	8	4.4	179.9	(77.5-354.6)	Male	19	19.9	95.5	(57.5-149.2)
<u>Leukemia</u>					Female	71	67.0	106.0	(82.8-133.8)
Male	28	35.3	79.4	(52.7-114.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	38	29.9	127.0	(89.9-174.4)	Female	94	84.5	111.2	(89.8-136.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	30	26.5	113.3	(76.4-161.7)	Male	1352	1262.4	107.1	(101.5-113.0)
Female	9	10.7	83.9	(38.3-159.3)	Female	1304	1374.3	94.9	(89.8-100.2)
<u>Lung and Bronchus</u>									
Male	266	172.4	154.3	(136.3-174.0)					
Female	199	197.1	101.0	(87.4-116.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	60.7	107.2	(82.7-136.6)	Male	32	35.5	90.2	(61.7-127.3)
Female	15	22.0	68.0	(38.0-112.2)	Female	27	25.9	104.1	(68.6-151.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	9.0	122.0	(60.8-218.4)	Male	11	9.5	115.4	(57.5-206.5)
Female	10	8.0	124.4	(59.6-228.8)	Female	7	7.9	89.1	(35.7-183.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.8	nc	(nc-nc)	Male	32	30.4	105.1	(71.9-148.4)
Female	219	200.7	109.1	(95.2-124.6)	Female	22	27.0	81.5	(51.1-123.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.4	78.0	(25.1-182.0)	Male	21	20.7	101.3	(62.7-154.9)
<u>Colon / Rectum</u>					Female	9	10.4	86.6	(39.5-164.3)
Male	63	68.7	91.7	(70.4-117.3)	<u>Ovary</u>				
Female	54	69.7	77.4	(58.2-101.1)	Female	27	19.7	137.1	(90.3-199.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	15.2	92.1	(50.3-154.5)	Male	23	19.2	119.6	(75.8-179.5)
Female	6	4.6	130.1	(47.5-283.3)	Female	19	20.8	91.1	(54.8-142.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.1	nc	(nc-nc)	Male	218	224.0	97.3	(84.8-111.1)
Female	4	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	13.5	81.5	(40.6-145.9)
Male	29	29.2	99.4	(66.6-142.8)	Female	5	8.0	62.2	(20.0-145.1)
Female	13	17.8	73.1	(38.9-125.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.8	131.4	(42.3-306.6)
Male	8	8.8	91.0	(39.2-179.4)	<u>Thyroid</u>				
Female	3	2.6	nc	(nc-nc)	Male	11	9.5	115.5	(57.6-206.7)
<u>Leukemia</u>					Female	20	28.5	70.1	(42.8-108.2)
Male	20	19.8	101.0	(61.7-156.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	14.6	75.4	(37.6-134.9)	Female	42	47.8	87.8	(63.3-118.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	15.7	95.8	(53.6-158.0)	Male	729	766.9	95.1	(88.3-102.2)
Female	2	5.7	nc	(nc-nc)	Female	684	724.2	94.4	(87.5-101.8)
<u>Lung and Bronchus</u>									
Male	88	111.4	79.0	(63.3-97.3)					
Female	107	114.4	93.5	(76.6-113.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	38.6	72.5	(48.2-104.8)	Male	17	25.5	66.8	(38.9-106.9)
Female	13	13.7	95.0	(50.5-162.4)	Female	16	21.0	76.1	(43.5-123.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.8	89.8	(36.0-185.0)	Male	11	6.4	173.0	(86.2-309.5)
Female	6	6.6	90.8	(33.2-197.6)	Female	6	4.9	121.3	(44.3-264.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	31	22.5	137.8	(93.6-195.5)
Female	117	145.1	80.6	(66.7-96.6)	Female	25	18.1	138.2	(89.4-204.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.9	nc	(nc-nc)	Male	20	15.1	132.2	(80.7-204.2)
<u>Colon / Rectum</u>					Female	5	7.3	68.9	(22.2-160.9)
Male	26	46.4	56.1	(36.6-82.1)	<u>Ovary</u>				
Female	40	45.7	87.6	(62.6-119.3)	Female	15	14.1	106.5	(59.6-175.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.9	110.8	(55.2-198.2)	Male	12	12.4	97.1	(50.1-169.6)
Female	5	2.8	180.2	(58.1-420.4)	Female	11	12.9	85.1	(42.4-152.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.9	155.4	(56.7-338.2)	Male	111	141.6	78.4	(64.5-94.4)
Female	2	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	8.9	67.4	(24.6-146.7)
Male	23	20.7	111.3	(70.5-167.0)	Female	6	5.3	114.2	(41.7-248.7)
Female	12	11.9	100.7	(52.0-175.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	6.4	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	3	8.5	nc	(nc-nc)
<u>Leukemia</u>					Female	14	28.1	49.7	(27.2-83.5)
Male	14	14.6	95.7	(52.3-160.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.7	102.9	(51.3-184.1)	Female	48	33.0	145.3	(107.1-192.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	11.0	54.6	(19.9-118.8)	Male	460	517.7	88.9	(80.9-97.4)
Female	3	3.8	nc	(nc-nc)	Female	481	504.9	95.3	(86.9-104.2)
<u>Lung and Bronchus</u>									
Male	82	70.7	116.0	(92.3-144.0)					
Female	83	69.3	119.8	(95.4-148.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	12	15.7	76.4	(39.4-133.5)
Female	0	0.1	nc	(nc-nc)	Female	10	9.3	107.6	(51.5-197.9)
<u>Lung and Bronchus</u>									
Male	2	2.3	nc	(nc-nc)					
Female	3	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.6	107.9	(64.9-168.5)	Male	13	11.8	110.6	(58.8-189.2)
Female	3	6.0	nc	(nc-nc)	Female	11	9.2	119.1	(59.4-213.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	143.2	(46.1-334.1)	Male	2	3.0	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	10.2	78.7	(33.9-155.2)
Female	66	68.0	97.1	(75.1-123.5)	Female	8	8.1	99.3	(42.8-195.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	189.6	(61.1-442.4)	Male	5	7.2	69.7	(22.5-162.7)
<u>Colon / Rectum</u>					Female	5	3.3	153.7	(49.5-358.6)
Male	25	21.1	118.3	(76.5-174.6)	<u>Ovary</u>				
Female	30	19.7	152.7	(103.0-217.9)	Female	11	6.3	174.4	(87.0-312.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.7	nc	(nc-nc)	Male	7	5.7	121.9	(48.8-251.2)
Female	0	1.3	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	65	68.3	95.2	(73.5-121.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.1	172.2	(69.0-354.7)
Male	10	9.8	102.1	(48.9-187.8)	Female	2	2.2	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.3	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	12.4	89.0	(44.3-159.2)
Male	5	6.5	77.4	(24.9-180.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	4.5	198.3	(90.5-376.5)	Female	20	15.4	129.7	(79.2-200.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.2	nc	(nc-nc)	Male	242	240.3	100.7	(88.4-114.2)
Female	0	1.7	nc	(nc-nc)	Female	243	228.4	106.4	(93.4-120.6)
<u>Lung and Bronchus</u>									
Male	29	33.2	87.4	(58.5-125.6)					
Female	30	32.4	92.5	(62.4-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	69.5	80.6	(60.9-104.7)	Male	32	46.0	69.6	(47.6-98.3)
Female	29	26.2	110.5	(74.0-158.8)	Female	27	37.5	72.0	(47.4-104.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	13.5	118.6	(67.8-192.6)	Male	15	11.4	131.3	(73.4-216.6)
Female	10	11.9	84.3	(40.4-155.0)	Female	11	9.4	117.0	(58.3-209.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.0	nc	(nc-nc)	Male	39	40.0	97.4	(69.3-133.2)
Female	282	262.4	107.5	(95.3-120.8)	Female	28	33.8	82.9	(55.0-119.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.3	77.4	(33.3-152.4)	Male	14	27.4	51.1	(27.9-85.8)
<u>Colon / Rectum</u>					Female	17	13.3	128.0	(74.5-204.9)
Male	82	84.3	97.3	(77.3-120.7)	<u>Ovary</u>				
Female	103	86.9	118.5	(96.8-143.8)	Female	21	25.7	81.8	(50.6-125.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	17.9	122.9	(77.0-186.1)	Male	16	22.3	71.8	(41.0-116.6)
Female	10	5.4	186.6	(89.3-343.2)	Female	19	24.9	76.3	(45.9-119.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	6.2	nc	(nc-nc)	Male	262	256.5	102.1	(90.1-115.3)
Female	4	5.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	16.2	105.2	(61.2-168.5)
Male	36	37.1	96.9	(67.9-134.2)	Female	15	10.1	149.2	(83.4-246.1)
Female	16	22.2	72.2	(41.3-117.3)	<u>Testis</u>				
<u>Larynx</u>					Male	8	11.0	72.9	(31.4-143.7)
Male	5	10.4	47.9	(15.4-111.9)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	18	15.2	118.3	(70.1-187.0)
<u>Leukemia</u>					Female	43	48.1	89.4	(64.7-120.4)
Male	28	25.6	109.2	(72.6-157.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	19.9	150.8	(101.7-215.2)	Female	59	59.9	98.5	(74.9-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	16	19.7	81.2	(46.4-131.9)	Male	890	930.2	95.7	(89.5-102.2)
Female	6	7.1	84.4	(30.8-183.7)	Female	966	930.4	103.8	(97.4-110.6)
<u>Lung and Bronchus</u>									
Male	115	126.0	91.3	(75.4-109.6)					
Female	124	132.1	93.9	(78.1-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2005-2009

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	24.7	154.0	(109.0-211.4)	Male	16	18.0	89.0	(50.8-144.6)
Female	8	8.1	98.3	(42.3-193.7)	Female	14	14.8	94.5	(51.6-158.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.9	102.5	(37.4-223.2)	Male	5	4.3	116.8	(37.6-272.5)
Female	2	4.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	15.9	69.2	(34.5-123.9)
Female	101	103.4	97.6	(79.5-118.6)	Female	15	11.4	131.2	(73.4-216.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.6	nc	(nc-nc)	Male	14	11.5	122.1	(66.7-204.9)
<u>Colon / Rectum</u>					Female	5	4.8	105.1	(33.9-245.3)
Male	33	32.0	103.3	(71.1-145.0)	<u>Ovary</u>				
Female	37	28.1	131.7	(92.8-181.6)	Female	10	9.4	106.1	(50.8-195.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.8	73.8	(23.8-172.2)	Male	8	8.2	98.0	(42.2-193.0)
Female	4	1.7	nc	(nc-nc)	Female	10	7.6	130.8	(62.6-240.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.7	nc	(nc-nc)	Male	136	96.1	141.6	(118.8-167.4)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.0	nc	(nc-nc)
Male	18	15.0	119.9	(71.0-189.5)	Female	2	3.1	nc	(nc-nc)
Female	7	7.9	88.3	(35.4-182.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.7	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	7	6.7	105.0	(42.0-216.3)
<u>Leukemia</u>					Female	29	21.6	134.0	(89.7-192.5)
Male	9	10.1	89.0	(40.6-169.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.0	71.6	(23.1-167.0)	Female	17	22.4	75.9	(44.2-121.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.0	87.9	(35.2-181.2)	Male	390	353.4	110.4	(99.7-121.9)
Female	2	2.4	nc	(nc-nc)	Female	346	336.8	102.7	(92.2-114.1)
<u>Lung and Bronchus</u>									
Male	37	45.5	81.4	(57.3-112.2)					
Female	38	42.5	89.3	(63.2-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;